Cargando…
Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
Autores principales: | Hirshberg, Boaz, Raz, Itamar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632144/ https://www.ncbi.nlm.nih.gov/pubmed/21525438 http://dx.doi.org/10.2337/dc11-s202 |
Ejemplares similares
-
Sibutramine on Cardiovascular Outcome
por: Scheen, André J.
Publicado: (2011) -
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses
por: Ginsberg, Henry N.
Publicado: (2011) -
Diabetes, Hypertension, and Outcome Studies: Overview 2010
por: Nilsson, Peter M., et al.
Publicado: (2011) -
Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations
por: Hirshberg, Boaz, et al.
Publicado: (2013) -
Individualization of Antihypertensive Drug Treatment
por: Mancia, Giuseppe, et al.
Publicado: (2013)